Takeda Pharmaceutical Co Ltd (NYSE:TAK) has decided to voluntarily withdraw its lung cancer drug, Exkivity, from the US market following a failed confirmatory trial. The company is also planning to initiate a global withdrawal where the drug is approved. The decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint. Takeda will continue to assess the impact of the withdrawal and update the full-year, consolidated forecast for the fiscal year ending March 31, 2024.